# Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P

> **NCT02634008** · PHASE3 · COMPLETED · sponsor: **Kirby Institute** · enrollment: 83 (actual)

## Conditions studied

- Hepatitis C, Acute

## Interventions

- **DRUG:** Paritaprevir/ritonavir/ombitasvir
- **DRUG:** Dasabuvir
- **DRUG:** Ribavirin
- **DRUG:** Glecaprevir/pibrentasvir

## Key facts

- **NCT ID:** NCT02634008
- **Lead sponsor:** Kirby Institute
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2021-04-30
- **Final completion:** 2021-04-30
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2022-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02634008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02634008, "Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02634008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*